Karyopharm Therapeutics (KPTI) Invested Capital (2016 - 2025)
Karyopharm Therapeutics (KPTI) has disclosed Invested Capital for 14 consecutive years, with -$271.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Invested Capital fell 46.18% year-over-year to -$271.9 million, compared with a TTM value of -$271.9 million through Dec 2025, down 46.18%, and an annual FY2025 reading of -$271.9 million, down 46.18% over the prior year.
- Invested Capital was -$271.9 million for Q4 2025 at Karyopharm Therapeutics, down from -$256.8 million in the prior quarter.
- Across five years, Invested Capital topped out at -$16.7 million in Q4 2022 and bottomed at -$271.9 million in Q4 2025.
- Average Invested Capital over 5 years is -$132.6 million, with a median of -$129.1 million recorded in 2021.
- The sharpest move saw Invested Capital soared 79.09% in 2022, then plummeted 717.76% in 2023.
- Year by year, Invested Capital stood at -$79.7 million in 2021, then skyrocketed by 79.09% to -$16.7 million in 2022, then crashed by 717.76% to -$136.2 million in 2023, then plummeted by 36.57% to -$186.0 million in 2024, then tumbled by 46.18% to -$271.9 million in 2025.
- Business Quant data shows Invested Capital for KPTI at -$271.9 million in Q4 2025, -$256.8 million in Q3 2025, and -$232.7 million in Q2 2025.